A real world retrospective study to assess the impact of Bamlanivimab monotherapy versus Bamlanivimab-Etesevimab combination on hospitalization and mortality among a real-world high-risk cohort of outpatients with COVID-19
Latest Information Update: 05 Oct 2022
At a glance
- Drugs Bamlanivimab (Primary) ; Etesevimab (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- 01 Sep 2022 Results published in the Journal of Clinical Pharmacy and Therapeutics
- 07 Feb 2022 New trial record